We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+19.87%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.6B
AUM Growth
+$244M
Cap. Flow
+$74.7M
Cap. Flow %
4.68%
Top 10 Hldgs %
27.52%
Holding
150
New
14
Increased
55
Reduced
10
Closed
13

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$36M
2
AMRN
Amarin Corp
AMRN
+$13.9M
3
TSRO
TESARO, Inc.
TSRO
+$13.7M
4
DHR icon
Danaher
DHR
+$12.8M
5
PTHN
Patheon N.V.
PTHN
+$11M

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$19.8M
2
HTWR
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
+$18M
3
TMO icon
Thermo Fisher Scientific
TMO
+$14.8M
4
MD icon
Pediatrix Medical
MD
+$9.92M
5
XNPT
XENOPORT, INC.
XNPT
+$8.41M

Sector Composition

Rank Sector Weight
1 Healthcare 81.88%
2 Financials 3.67%
3 Industrials 0.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSRO
1
DELISTED
TESARO, Inc.
TSRO
$62.8M 3.94%
626,500
+146,500
+31% +$13.7M
AET
2
DELISTED
Aetna Inc
AET
$50.8M 3.19%
440,100
– –
RDUS
3
DELISTED
Radius Health, Inc.
RDUS
$48.2M 3.02%
892,000
+24,500
+3% +$1.25M
ACHC icon
4
Acadia Healthcare
ACHC
$2.52B
$45.8M 2.87%
924,678
+87,678
+10% +$4.57M
GWPH
5
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$43.1M 2.7%
325,000
+55,000
+20% +$5.26M
AGN
6
DELISTED
Allergan plc
AGN
$42.8M 2.69%
186,000
+4,900
+3% +$1.2M
ONCE
7
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$37.5M 2.35%
625,000
+15,000
+2% +$865K
MRK icon
8
Merck
MRK
$322B
$36.7M 2.3%
+615,700
New +$36M
PFE icon
9
Pfizer
PFE
$143B
$35.8M 2.24%
1,112,813
– –
AAAP
10
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$35.4M 2.22%
930,000
+9,000
+1% +$300K
ALXN
11
DELISTED
Alexion Pharmaceuticals
ALXN
$32.7M 2.05%
267,250
+31,750
+13% +$4.09M
ISRG icon
12
Intuitive Surgical
ISRG
$127B
$32.6M 2.04%
405,000
+9,000
+2% +$689K
HCA icon
13
HCA Healthcare
HCA
$90.6B
$32.5M 2.04%
430,000
– –
CI icon
14
Cigna
CI
$78.4B
$29.8M 1.87%
228,500
+21,700
+10% +$2.83M
COLL icon
15
Collegium Pharmaceutical
COLL
$1.18B
$29.8M 1.87%
1,545,000
+330,000
+27% +$3.92M
WCG
16
DELISTED
Wellcare Health Plans, Inc.
WCG
$27.5M 1.72%
234,500
– –
GILD icon
17
Gilead Sciences
GILD
$165B
$27.2M 1.71%
344,000
+300
+0.1% +$24.4K
CELG
18
DELISTED
Celgene Corp
CELG
$26.6M 1.67%
254,500
– –
ACRS icon
19
Aclaris Therapeutics
ACRS
$715M
$26M 1.63%
1,016,000
+16,000
+2% +$339K
MDCO
20
DELISTED
Medicines Co
MDCO
$25.7M 1.61%
681,000
+500
+0.1% +$18.8K
SHPG
21
DELISTED
Shire pic
SHPG
$25.7M 1.61%
132,500
+12,458
+10% +$2.43M
ARDX icon
22
Ardelyx
ARDX
$1.24B
$25.6M 1.6%
1,975,000
+700,000
+55% +$7.33M
LLY icon
23
Eli Lilly
LLY
$1.08T
$22.2M 1.39%
276,000
– –
TBPH icon
24
Theravance Biopharma
TBPH
$873M
$21.7M 1.36%
600,000
-100,000
-14% -$2.78M
CLSD
25
DELISTED
Clearside Biomedical
CLSD
$21.3M 1.33%
81,667
-8,555
-9% -$1.05M
1
2 3 4 5

Similar funds

AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
SGI
Summit Global Investments Bountiful, Utah $1.69B AUM 12.13% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
ISS
Intesa Sanpaolo SpA. Turin, Italy $1.69B AUM
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return

Rock Springs Capital Management's Q3 2016 Portfolio in Review

As of Q3 2016, Rock Springs Capital Management held 150 positions worth $1.6B, up 18% from $1.35B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Rock Springs Capital Management deployed $74.7M of net new capital in Q3 2016, opening 14 new positions and adding to 55 existing holdings. Its largest new stake was Merck: 615,700 shares worth $36.7M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 78% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Pediatrix Medical, an estimated $9.92M trimmed.

  • Rock Springs Capital Management's largest Q3 2016 buy was Merck: 615,700 shares worth $36.7M.
  • Rock Springs Capital Management added most to TESARO, Inc. in Q3 2016, an estimated $13.7M increase.
  • Rock Springs Capital Management's biggest Q3 2016 reduction was Pediatrix Medical, cutting an estimated $9.92M.
  • Rock Springs Capital Management fully exited Teva Pharmaceuticals in Q3 2016, selling an estimated $19.8M.
  • Rock Springs Capital Management's ten largest holdings make up 28% of its $1.6B portfolio in Q3 2016.
  • Rock Springs Capital Management opened 14 new positions and closed 13 in Q3 2016.
  • Rock Springs Capital Management's portfolio value rose 18% quarter-over-quarter to $1.6B.

Based on Rock Springs Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.